Autopsy report · NCT01290887
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Cause of deathFunding or business
“Business decision”
Life of this trial
- Registered 4 months before it started.
- Ran for about 3 years 7 months before it stopped.
- 1,052 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Sponsor type
- Industry
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab
- Participants
- 1,052
- Sites
- 219
- Countries
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.